{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:10:30Z","timestamp":1780384230562,"version":"3.54.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.cjca.2020.03.041","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T18:01:10Z","timestamp":1586109670000},"page":"1372-1383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-6860","authenticated-orcid":false,"given":"Michael","family":"Khoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"McCrindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2020.03.041_bib1","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.03.041_bib2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/01.ATV.20.8.1998","article-title":"Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth: the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group","volume":"20","author":"McGill","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2020.03.041_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archinte.1996.00440110083011","article-title":"Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study","volume":"156","author":"Bao","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2020.03.041_bib4","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association","volume":"139","author":"de Ferranti","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib5","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: Executive Summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib6","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib7","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","volume":"115","author":"McCrindle","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib8","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"issue":"suppl 5","key":"10.1016\/j.cjca.2020.03.041_bib9","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.cjca.2020.03.041_bib10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib11","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib12","first-page":"1553","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2020.03.041_bib14","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Quebec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.cjca.2020.03.041_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.49.3.476","article-title":"Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia","volume":"49","author":"Stone","year":"1974","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.03.041_bib19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.03.041_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2012.10.032","article-title":"Statin treatment of children with familial hypercholesterolemia\u2013trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?","volume":"226","author":"Vuorio","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2020.03.041_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.03.041_bib22","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1161\/01.CIR.98.23.2580","article-title":"Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia","volume":"98","author":"Gidding","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib23","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2020.03.041_bib24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.97.5.619","article-title":"Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group","volume":"97","author":"Lambert","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.cjca.2020.03.041_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1203\/00006450-199605000-00021","article-title":"Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia","volume":"39","author":"Knipscheer","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1016\/j.cjca.2020.03.041_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.ATV.18.6.1007","article-title":"Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia","volume":"18","author":"Couture","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2020.03.041_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.03.041_bib28","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy\u00a0in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","author":"de Jongh","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib30","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1542\/peds.2004-2090","article-title":"Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia","volume":"116","author":"Clauss","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.cjca.2020.03.041_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/08035250600702602","article-title":"Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia","volume":"95","author":"van der Graaf","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib32","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia","volume":"55","author":"Avis","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.106.671016","article-title":"Statin treatment in children with familial hypercholesterolemia: the younger, the better","volume":"116","author":"Rodenburg","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.03.041_bib35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.03.041_bib36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0735-1097(02)02593-7","article-title":"Early statin therapy restores endothelial function in children with familial hypercholesterolemia","volume":"40","author":"de Jongh","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib38","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management: a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2020.03.041_bib39","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2009.04.054","article-title":"Atherosclerosis in survivors of Kawasaki disease","volume":"155","author":"Gupta-Malhotra","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib41","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jacc.2013.04.090","article-title":"Vascular health in Kawasaki disease","volume":"62","author":"Selamet Tierney","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038998","article-title":"Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study","volume":"7","author":"Orenstein","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2020.03.041_bib43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2362.1994.tb01074.x","article-title":"Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis","volume":"24","author":"Munro","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjca.2020.03.041_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2014.10.057","article-title":"Statin reduces persistent coronary arterial inflammation evaluated by serial (1)(8)fluorodeoxyglucose positron emission tomography imaging long after Kawasaki disease","volume":"179","author":"Suda","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12519-014-0498-5","article-title":"Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease","volume":"10","author":"Duan","year":"2014","journal-title":"World J Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib46","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1253\/circj.CJ-08-0121","article-title":"Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study","volume":"72","author":"Huang","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2020.03.041_bib47","first-page":"245","article-title":"Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease","volume":"56","author":"Hamaoka","year":"2010","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2019.07.064","article-title":"Phase I\/IIa trial of atorvastatin in patients with acute Kawasaki disease with coronary artery aneurysm","volume":"215","author":"Tremoulet","year":"2019","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jacc.2015.05.063","article-title":"Improved detection of cardiac allograft vasculopathy: a multi-institutional analysis of functional parameters in pediatric heart transplant recipients","volume":"66","author":"Kindel","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib50","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.healun.2019.08.002","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-second pediatric heart transplantation report-2019; focus theme: donor and recipient size match","volume":"38","author":"Rossano","year":"2019","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib51","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.healun.2006.06.003","article-title":"Hyperlipidemia in children after heart transplantation","volume":"25","author":"Singh","year":"2006","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/acs.2018.01.07","article-title":"Current state of pediatric cardiac transplantation","volume":"7","author":"Dipchand","year":"2018","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cjca.2020.03.041_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2020.03.041_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.healun.2003.10.013","article-title":"Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation","volume":"24","author":"Mahle","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1399-3046.2007.00827.x","article-title":"Prevention of pediatric graft coronary artery disease: atorvastatin","volume":"12","author":"Chin","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.healun.2015.10.040","article-title":"Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents","volume":"35","author":"Greenway","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.cjca.2020.03.041_bib57","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jcmg.2018.04.025","article-title":"Optical coherence tomography for the early detection of coronary vascular changes in children and adolescents after cardiac transplantation: findings from the International Pediatric OCT Registry","volume":"12","author":"McGovern","year":"2019","journal-title":"JACC Cardiovasc Img"},{"key":"10.1016\/j.cjca.2020.03.041_bib58","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1681\/ASN.2011111115","article-title":"Cardiovascular disease in children with chronic kidney disease","volume":"23","author":"Mitsnefes","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2020.03.041_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.30645","article-title":"Use of atorvastatin in systemic lupus erythematosus in children and adolescents","volume":"64","author":"Schanberg","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cjca.2020.03.041_bib60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/annrheumdis-2012-202315","article-title":"Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein","volume":"73","author":"Ardoin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cjca.2020.03.041_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/INF.0000000000001352","article-title":"Safety and efficacy of atorvastatin in human immunodeficiency virus-infected children, adolescents and young adults with hyperlipidemia","volume":"36","author":"Melvin","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cjca.2020.03.041_bib62","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2337\/dc06-0310","article-title":"Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for Diabetes in Youth study","volume":"29","author":"Rodriguez","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2020.03.041_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/pedi.12245","article-title":"A\u00a0randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes","volume":"16","author":"Canas","year":"2015","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.cjca.2020.03.041_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1515\/JPEM.2009.22.1.65","article-title":"Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus","volume":"22","author":"Haller","year":"2009","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"10.1016\/j.cjca.2020.03.041_bib65","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2020.03.041_bib66","first-page":"CD006401","article-title":"Statins for children with familial hypercholesterolemia","author":"Vuorio","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2020.03.041_bib67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/MPG.0000000000002174","article-title":"Hepatotoxicity of statins as determined by serum alanine aminotransferase in a pediatric cohort with dyslipidemia","volume":"68","author":"Desai","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cjca.2020.03.041_bib68","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.03.041_bib69","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1161\/ATVBAHA.107.145151","article-title":"A\u00a0systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia","volume":"27","author":"Avis","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2020.03.041_bib70","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpeds.2017.02.047","article-title":"Statin-associated myopathy in a pediatric preventive cardiology practice","volume":"185","author":"Johnson","year":"2017","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib71","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.03.041_bib72","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2020.03.041_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2015.07.107","article-title":"Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: the SAFEHEART study","volume":"201","author":"Fuentes","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib74","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2015.05.006","article-title":"Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk","volume":"167","author":"Braamskamp","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib75","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","author":"Braamskamp","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2020.03.041_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00246-013-0746-9","article-title":"Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms","volume":"35","author":"Niedra","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.cjca.2020.03.041_bib77","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1651-2227.2003.tb02584.x","article-title":"Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents","volume":"92","author":"de Jongh","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.cjca.2020.03.041_bib78","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1471-0528.2008.02084.x","article-title":"Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance","volume":"116","author":"Thorogood","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.cjca.2020.03.041_bib79","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.03.041_bib80","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2020.03.041_bib81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.03.041_bib82","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2020.03.041_bib83","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jacl.2018.05.007","article-title":"Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study","volume":"12","author":"Gaudet","year":"2018","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20303147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X20303147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:07Z","timestamp":1760107387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X20303147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0828282X20303147"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2020.03.041","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2020.03.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}